Safety, Feasibility and Efficacy of Sulforaphane (Avmacol Extra Strength) in Chronic Kidney Disease
Status:
Not yet recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
The Sulforaphane Production System® in Avmacol Extra Strength (ES) supplies broccoli seed
extract (glucoraphanin) and Myrosimax® (Active Myrosinase Enzyme) which helps promote
sulforaphane production in your body. The investigators hypothesize that daily intake of
Avmacol ES can decrease kidney disease progression rate and decrease markers of oxidative
stress and inflammation in Chronic Kidney Disease (CKD) patients. They will test this
hypothesis in a randomized, double-blind, placebo controlled Phase 2 clinical trial. This
proposed study has been funded by the National Institute of Diabetes and Digestive and Kidney
Diseases (NIDDK), R01 DK128677.
Phase:
Phase 2
Details
Lead Sponsor:
University of Rochester
Collaborators:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Nutramax Laboratories, Inc. University of Virginia